Separately, Piper Jaffray Companies started coverage on shares of Arsanis in a report on Monday. They set an overweight rating and a $23.00 price objective on the stock.
Shares of Arsanis (ASNS) traded down $1.75 during trading on Monday, reaching $12.22. 125,200 shares of the company’s stock were exchanged, compared to its average volume of 41,925. Arsanis has a fifty-two week low of $12.21 and a fifty-two week high of $19.73.
In related news, Director Tillman U. Gerngross acquired 200,000 shares of the stock in a transaction on Monday, November 20th. The shares were acquired at an average price of $10.00 per share, for a total transaction of $2,000,000.00. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Polaris Venture Management Co. acquired 500,000 shares of the stock in a transaction on Monday, November 20th. The stock was bought at an average price of $10.00 per share, for a total transaction of $5,000,000.00. The disclosure for this purchase can be found here.
ILLEGAL ACTIVITY NOTICE: “Arsanis (ASNS) Receives New Coverage from Analysts at Cowen” was originally reported by Stock Observer and is owned by of Stock Observer. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.thestockobserver.com/2017/12/12/arsanis-asns-receives-new-coverage-from-analysts-at-cowen.html.
Arsanis, Inc is a biopharmaceutical company. The Company is focused on the discovering and developing monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. The Company’s mAbs focus on specific pathogens and pathogenic processes. Its product pipeline includes ASN100, ASN200, ASN300, ASN400 and ASN500.
Receive News & Ratings for Arsanis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.